Can Fam Physician Vol.
54, No. 1, January
2008,
pp.36
-
38
Copyright © 2008 by The College of Family Physicians of Canada
Folic acid and prevention of neural tube defects
Milly Ryan-Harshman, PhD RD
Registered dietitian and owner of FEAST Enterprises in Oshawa, Ont
Walid Aldoori, MB BCh MPA ScD
Medical Director at Wyeth Consumer Healthcare Inc in Mississauga, Ont
Maternal folate status is involved in the pathogenesis of neural tube defects (NTDs), and although the exact mechanism is not clear, a nutritional or genetic defect in homocysteine metabolism via methionine synthase appears likely. Women who previously had infants with NTDs were found to have had higher plasma homo-cysteine levels than women who had normal offspring.1,2
Higher homocysteine levels can be indicative of the presence of a metabolic defect that increases risk of NTDs or other congenital defects. The rapidly dividing cells of the neural tube can be particularly sensitive to folate because of its importance to methyl group metabolism in nucleic acid and amino acid biosynthesis.3
Certainly, the scientific evidence that folic acid taken around the time of conception prevents many NTDs has been very strong.4 In Canada starting in January 1998, flour and pasta were fortified with folic acid to help prevent NTDs, and results have been very encouraging.5 In Europe, recommendations to increase folic acid through voluntary supplementation did not reduce the incidence of NTDs; however, food fortification had not been implemented.6 Interestingly enough, however, when physicians took an active role in promoting folic acid supplementation, folic acid intake increased. Women who received folic acid counseling, a 30-day supply of folic acid tablets, and a reminder telephone call increased their folic acid intake by 68%, compared with 20% of controls who received only a pamphlet on folic acid.7
Periconceptional use of folic acid has been shown to reduce the incidence of non-NTD birth defects, such as cleft palates, upper limb reduction deficits, and genitourinary defects.8 Others have also observed a link between folic acid and congenital heart defects, urinary tract anomalies, orofacial clefts, limb defects, and pyloric stenosis.9
 |
Recommendations on folic acid supplementation
|
|---|
Before fortification, mean intakes of folate in Canada were less than 200 µg/d, though folate content in foods generally has been underestimated. United States data placed the average folate intake at about 250 µg/d.10 Fortification increases dietary consumption by up to 100 µg/d or about 25% of the recommended daily allowance.11 During pregnancy, folic acid should be increased to 600 µg/d.10 Many pregnancies are unplanned, and women often do not know that they are pregnant until the crucial first 4 to 8 weeks of pregnancy. This is the time during which neural tube development occurs, hence the importance of ensuring adequate folic acid intake. Therefore, to achieve the greatest benefit in NTD risk reduction, women of child-bearing age should be consuming total folic acid intakes of at least 400 µg, and probably 600 µg, daily. A daily supplement of 400 µg of folic acid should remain an important component of NTD prevention.12
Some individuals might have a greater requirement for folic acid based upon their ethnic background. One study determined that in the Welsh population, about 12% of people have the TT genotype of the methylenetet-rahydrofolate reductase 677C T mutation. Therefore, the studys authors suggested that a folate-enrichment policy be formulated to help these individuals achieve intakes between 400 and 600 µg/d.13 In another study, women with the TT genotype appeared to benefit the most from folic acid supplementation intended to lower plasma total homocysteine.14 In Canada, women of First Nations origin had a higher risk of having an NTD-affected pregnancy than did white women. Although obesity and type 2 diabetes could have been the risk factors for these NTDs, other mechanisms that might be related to folate status should be explored within this population.15
Overall, the goal should be to increase red blood cell folate concentrations to greater than 905 nmol/L, a level associated with a low risk of having a child with an NTD. In women, a 400-µg daily dose of folic acid raised the red blood cell concentration to 1053 nmol/L from a baseline of 615 nmol/L after 12 weeks. This study also showed that a once-a-week folic acid supplement (2800 µg) also raised red blood cell folate concentrations, but not as effectively as a daily supplement.16 For women who have an intermediate to high risk of having an NTD-affected pregnancy, the Society of Obstetricians and Gynaecologists of Canada *recommends a daily intake of high-dose (4 to 5 mg) folic acid supplementation.17 Some studies have shown that lower doses of folic acid (300 µg or less) have the potential to lower total homocysteine concentrations, especially in those individuals who are in the higher range of homocysteine values.18,19 It is most important, however, that women of child-bearing age achieve adequate folate status through consumption of vegetables, fruit, and fortified grain products, and take folic acid in supplement form as a risk-reduction strategy.
 |
Footnotes
|
|---|
Competing interests
Dr Aldoori is employed by and Dr Ryan-Harshman received a grant to co-author this article from Wyeth Consumer Healthcare Inc.
* New, more extensive clinical practice guidelines were published in the December 2007 issue of the
Journal of Obstetrics and Gynaecology Canada20072912:1003–13
. 
 |
References
|
|---|
- Steegers-Theunissen RP, Boers GH, Trijbels FJ, Finkelstein JD, Blom HJ, Thomas CM, et al. Maternal hyperhomocysteinemia: a risk factor for neural-tube defects? Metabolism 1994;43(12):1475-80.[Medline]
- Mills JL, McPartlin JM, Kirke PN, Lee YJ, Conley MR, Weir DG, et al. Homocysteine metabolism in pregnancies complicated by neural-tube defects. Lancet 1995;345:791.[Medline]
- Green NS. Folic acid supplementation and prevention of birth defects. J Nutr 2002;132(8 Suppl):2356S-60S.[Abstract/Free Full Text]
- MRC Vitamin Study Research Group. Prevention of neural tube defects: results of the Medical Research Council vitamin study. Lancet 1991;338:131-7.[Medline]
- Ray JG, Meier C, Vermeulen MJ, Boss S, Wyatt PR, Cole DE. Association of neural tube defects and folic acid food fortification in Canada. Lancet 2002;360:2047-8.[Medline]
- Botto LD, Lisi A, Robert-Gnansia E, Eriskson JD, Vollset SE, Mastroiacovo P, et al. International retrospective cohort study of neural tube defects in relation to folic acid recommendations: are the recommendations working? BMJ 2005;330(7491):571. Epub 2005 Feb 18.[Abstract/Free Full Text]
- Robbins JM, Cleves MA, Collins HB, Andrews N, Smith LN, Hobbs CA. Randomized trial of a physician-based intervention to increase the use of folic acid supplements among women. Am J Obstet Gynecol 2005;192:1126-32.[Medline]
- Canfield MA, Collins JS, Botto LD, Williams LJ, Mai CT, Kirby RS, et al. Changes in the birth prevalence of selected birth defects after grain fortification with folic acid in the United States: Findings from a multi-state population-based study. Birth Defects Res A Clin Mol Teratol 2005;73(10):679-89.[Medline]
- Hall JG. Folic acid: the opportunity that still exists. CMAJ 2000;162:1571-2.[Medline]
- Food and Nutrition Board, Institute of Medicine. Dietary reference intakes for thiamin, riboflavin, niacin, vitamin B6, folate, vitamin B12, pantothenic acid, biotin and choline. Washington, DC: National Academy Press; 1997.
- Tice JA, Ross E, Coxson PG, Rosenberg I, Weinstein MC, Hunink MGM, et al. Cost-effectiveness of vitamin therapy to lower plasma homo-cysteine levels for the prevention of coronary heart disease: effect of grain fortification and beyond. JAMA 2001;286:936-43.[Abstract/Free Full Text]
- Centers for Disease Control and Prevention (CDC). Use of dietary supplements containing folic acid among women of childbearing age—United States, 2005. MMWR Morb Mortal Wkly Rep 2005;54:955-8.[Medline]
- Ashfield-Watt PAL, Pullin CH, Whiting JM, Clark ZE, Moat SJ, Newcombe RG. Methylenetetrahydrofolate reductase 677C
Tgenotype modulates homocyste -ineresponses to a folate-rich diet ora low-dosefolic acidsupplement: A randomized controlled trial. Am J Clin Nutr 2002;76:180-6.[Abstract/Free Full Text] - Fohr IP, Prinz-Langenohl R, Brönstrup A, Bohlmann AM, Nau H, Berthold HK, et al. 5,10-Me thylenetetrahydrofolate reductase genotype determines the plasma homocysteine-lowering effect of supplementation with 5-methyltetrahydrofolate or folic acid in healthy young women. Am J Clin Nutr 2002;75:275-82.[Abstract/Free Full Text]
- Ray JC, Vermeulen MJ, Meier C, Cole DEC, Wyatt PR. Maternal ethnicity and risk of neural tube defects: a population-based study. CMAJ 2004;171:343-5.[Abstract/Free Full Text]
- Norsworthy B, Skeaff CM, Adank C, Green TJ. Effects of once-a-week or daily folic acid supplementation on red blood cell folate concentrations in women. Eur J Clin Nutr 2004;58:548-54.[Medline]
- Wilson RD, Davies G, Desilets V, Reid GJ, Summers A, Wyatt P, et al. The use of folic acid for the prevention of neural tube defects and other congenital anomalies. J Obstet Gynaecol Can 2003;25(11):959-73.[Medline]
- Brouwer IA, van Dusseldorp M, Thomas CMG, Duran M, Hautvast JGAJ, Eskes TKAB, et al. Low-dose folic acid supplementation decreases plasma homocysteine concentrations: a randomised trial. Indian Heart J 2000;52(7 Suppl):S53-8.[Medline]
- Venn BJ, Mann JI, Williams SM, Riddell LJ, Chisholm A, Harper MJ, et al. Assessment of three levels of folic acid on serum folate and plasma homocysteine: a randomised placebo-controlled double-blind dietary intervention trial. Eur J Clin Nutr 2002;56(8):748-54.[Medline]
This article has been cited by other articles:

|
 |

|
 |
 
M. McGuire, B. Cleary, L. Sahm, and D.J. Murphy
Prevalence and predictors of periconceptional folic acid uptake--prospective cohort study in an Irish urban obstetric population
Hum. Reprod.,
February 1, 2010;
25(2):
535 - 543.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|
|